stoxline Quote Chart Rank Option Currency Glossary
  
CollPlant Biotechnologies Ltd. (CLGN)
5.68  0.34 (6.37%)    02-23 15:57
Open: 5.4244
High: 5.731
Volume: 2,132
  
Pre. Close: 5.34
Low: 5.4
Market Cap: 65(M)
Technical analysis
2024-02-23 4:35:44 PM
Short term     
Mid term     
Targets 6-month :  6.77 1-year :  7.91
Resists First :  5.8 Second :  6.77
Pivot price 5.52
Supports First :  5.26 Second :  4.94
MAs MA(5) :  5.5 MA(20) :  5.46
MA(100) :  5.5 MA(250) :  6.55
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  56.9 D(3) :  55.2
RSI RSI(14): 54.9
52-week High :  11.49 Low :  4.69
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CLGN ] has closed below upper band by 27.4%. Bollinger Bands are 41.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.73 - 5.76 5.76 - 5.79
Low: 5.34 - 5.36 5.36 - 5.39
Close: 5.63 - 5.68 5.68 - 5.73
Company Description

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Headline News

Sat, 17 Feb 2024
Critical Review: CollPlant Biotechnologies (NASDAQ:CLGN) vs. Milestone Scientific (NYSE:MLSS) - Defense World

Thu, 15 Feb 2024
CollPlant Issues Letter to Shareholders - PR Newswire

Sat, 03 Feb 2024
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow - Simply Wall St

Mon, 08 Jan 2024
CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California - PR Newswire

Tue, 02 Jan 2024
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants - PR Newswire

Fri, 01 Dec 2023
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 11 (M)
Held by Insiders 8.13e+006 (%)
Held by Institutions 10.1 (%)
Shares Short 25 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.01e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin -62.8 %
Operating Margin -10 %
Return on Assets (ttm) 702.3 %
Return on Equity (ttm) -11.4 %
Qtrly Rev. Growth 1.072e+007 %
Gross Profit (p.s.) -147.81
Sales Per Share -48.15
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.12
Price to Cash Flow 0.82
Stock Dividends
Dividend 0
Forward Dividend 12360
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android